Message #21 From:
Stock News Bot Date: October 25, 2006 06:58:00 AM
PLRS News Dutton Associates Announces Investment Opinion: Pluristem Life Sciences Rating Raised to Speculative Buy by Dutton Associates
EL DORADO HILLS, Calif.--(BUSINESS WIRE)--Dutton Associates updates its coverage of Pluristem Life Sciences
(OTCBB:PLRS) raising its rating to Speculative Buy with a $.06 price
target. The research note by Dutton senior analyst William R. Prather,
R.Ph., M.D. is available at www.jmdutton.com
as well as from First Call, Bloomberg, Zacks, Reuters, Knobias, and
other leading financial portals.
Pluristem Life Systems, Inc. stock overhang from a previous overhang has
been worked through and the common stock could now significantly
appreciate as this selling pressure is reduced. Because we continue to
be enamored by Pluristem's technology we have, therefore, revised our
investment rating to Speculative Buy with a 12-month price target of
$0.06.
About Dutton Associates
Dutton Associates is one of the largest independent investment research
firms in the U.S. Its 31 senior analysts are primarily CFAs and have
expertise in many industries. Dutton Associates provides continuing
analyst coverage of over 140 enrolled companies, and its research,
estimates, and ratings are carried in all the major databases serving
institutions and online investors.
The cost of enrollment in our one-year continuing research program is US
$39,500 prepaid for 4 Research Reports, typically published quarterly,
and requisite Research Notes. Dutton Associates received $20,000 from
the Company for 2 Research Reports with coverage commencing on
9/06/2006. We do not accept payment of our fees in company stock. Our
principals and analysts are prohibited from owning or trading in
securities of covered companies. The views expressed in this research
report accurately reflect the analyst's personal views about the subject
securities or issuer. Neither the analyst's compensation nor the
compensation received by us is in any way related to the specific
ratings or views contained in this research report or note. Please read
full disclosures and analyst background at www.jmdutton.com
before investing.
